Core Insights - The company achieved a record total revenue of $1.4 billion for 2025, marking a 38% increase driven by a 52% surge in royalty revenue from core blockbuster franchises [1] Financial Performance - Revenue growth was significantly supported by DARZALEX FASPRO, which now holds a 97% share of sales in the U.S. [1] - PHESGO surpassed its initial 50% conversion target, reaching 54% [1] Strategic Acquisitions - The corporate profile was transformed from two to four drug delivery technologies through the acquisitions of Elektrofi (Hypercon) and Surf Bio, extending IP protection into the mid-2040s [1] - The acquisition of Surf Bio provides a second hyperconcentration technology, with clinical readiness targeted for the 2027 to 2028 timeframe [1] Product Portfolio Expansion - The ENHANZE portfolio expanded to 10 global blockbuster opportunities following regulatory approvals of RYBREVANT SC in the U.S., Japan, and China [1] Market Positioning - The company emphasizes a 'one-stop shop' model for biopharma, offering solutions across a wide range of modalities, including monoclonal antibodies, ADCs, and nucleic acids [1] - Management attributes the success of newer launches like OCREVUS ZUNOVO to their ability to overcome IV infusion capacity constraints, with 50% of U.S. patients being treatment-naive [1]